Interrupting growth hormone receptor signaling at midlife in mice extends lifespan, particularly in the longest-lived animals, while paradoxically increasing fat mass and decreasing lean mass without compromising strength or metabolic function. This finding suggests that growth hormone suppression in adulthood—rather than from birth—may offer a clinically viable approach to age-related disease reduction.
Key Points
- Growth hormone receptor knockout at midlife extended lifespan in both sexes, with females showing fo
- Increased adiposity and muscle loss occurred without inflammatory elevation, weakness, or metabolic
- Tissue-specific effects appeared: vertebral bone preservation in males, hepatic feminization in both
Longevity Analysis
This research separates two distinct questions: what happens when growth hormone signaling is disrupted from birth versus in adulthood. Earlier studies established that lifelong growth hormone suppression delays aging across multiple domains—metabolic control, cardiovascular resilience, cognitive function—mirroring the protection seen in humans with Laron syndrome. The current work demonstrates that interrupting this pathway at midlife still produces lifespan extension, which matters for clinical translation: it avoids disrupting normal growth and development while preserving the longevity benefit. The paradox—extended lifespan despite increased fat mass and muscle loss—suggests that growth hormone's role in aging operates independently of body composition metrics typically associated with healthspan. This indicates that growth hormone's effects on cellular metabolism, stress resilience, and tissue regeneration may be the operative longevity mechanisms, not simply its influence on musc
Original published by LifeSpan.io, by Josh Conway.